Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 36Terminated 4Active not recruiting 4Unknown 3Recruiting 2Withdrawn 1

Sponsor Class

NETWORK 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 86pembrolizumab 76Specimen Handling 75enzalutamide 55Radiosurgery 55Radiotherapy 51Docetaxel 50Androgen Antagonists 47Gemcitabine 42Nivolumab 39darolutamide 37Prednisone 35enfortumab vedotin 32Abiraterone Acetate 31Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28Standard of Care 28apalutamide 27Pluvicto 26abiraterone 25Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Flutamide × Genitourinary × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 3 Recruiting
1,273 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡